European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies
Identifieur interne : 000716 ( Istex/Corpus ); précédent : 000715; suivant : 000717European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies
Auteurs : M. Mosca ; C. Tani ; M. Aringer ; S. Bombardieri ; D. Boumpas ; R. Brey ; R. Cervera ; A. Doria ; D. Jayne ; M A Khamashta ; A. Kuhn ; C. Gordon ; M. Petri ; O P Rekvig ; M. Schneider ; Y. Sherer ; Y. Shoenfeld ; J S Smolen ; R. Talarico ; A. Tincani ; R F Van Vollenhoven ; M M Ward ; V P Werth ; L. CarmonaSource :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2010-07.
English descriptors
- Teeft :
- Active disease, American academy, Antimalarial drugs, Antiphospholipid antibodies, Ares, Arthritis, Arthritis rheum, Autoimmune diseases, Blood pressure, Bone mineral density, Cancer screening, Cardiovascular, Cardiovascular disease, Cardiovascular risk factors, Clinical practice, Cognitive impairment, Cutaneous, Cutaneous lupus disease area, Damage development, Delphi surveys, Diffuse proliferative lupus glomerulonephritis, Disease activity, Disease control, Disease progression, Erythematosus, Eular, European league, Further testing, General population, Glucocorticoid, Guideline, High dose glucocorticoids, High risk, Immunosuppressive drugs, Immunosuppressive therapy, Inactive disease, Kidney biopsy, Laboratory assessment, Lupus, Lupus erythematosus, Lupus nephritis, Lupus patients, Monitoring patients, Observational studies, Organ damage, Organ involvement, Oxford centre, Patient assessment, Predictive value, Premature atherosclerosis, Preventive measures, Protective antibodies, Recommendations table, Renal, Renal disease, Rheum, Rheumatic diseases, Rheumatol, Rheumatology, Risk factors, Serum creatinine, Severity index, Small group discussion, Standardised core, Supplementary material, Systematic literature review, Systemic, Systemic lupus erythematosus, Task force, Urine microscopy, Urine ratio, Vaccination, Visual analogue scale, Worse prognosis.
Abstract
Objectives To develop recommendations for monitoring patients with systemic lupus erythematosus (SLE) in clinical practice and observational studies and to develop a standardised core set of variables to monitor SLE. Methods We followed the European League Against Rheumatism (EULAR) standardised procedures for guideline development. The following techniques were applied: nominal groups, Delphi surveys for prioritisation, small group discussion, systematic literature review and two Delphi rounds to obtain agreement. The panel included rheumatologists, internists, dermatologists, a nephrologist and an expert related to national research agencies. The level of evidence and grading of recommendations were determined according to the Levels of Evidence and Grades of Recommendations of the Oxford Centre for Evidence-Based Medicine. Results A total of 10 recommendations have been developed, covering the following aspects: patient assessment, cardiovascular risk factors, other risk factors (osteoporosis, cancer), infection risk (screening, vaccination, monitoring), frequency of assessments, laboratory tests, mucocutaneous involvement, kidney monitoring, neuropsychological manifestations and ophthalmology assessment. A ‘core set’ of minimal variables for the assessment and monitoring of patients with SLE in clinical practice was developed that included some of the recommendations. In addition to the recommendations, indications for specific organ assessments that were viewed as part of good clinical practice were discussed and included in the flow chart. Conclusions A set of recommendations for monitoring patients with SLE in routine clinical practice has been developed. The use of a standardised core set to monitor patients with SLE should facilitate clinical practice, as well as the quality control of care for patients with SLE, and the collection and comparison of data in observational studies.
Url:
DOI: 10.1136/ard.2009.117200
Links to Exploration step
ISTEX:2543BEBD79DA58FAB1F39011EBF93221EDEADD0FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies</title><author><name sortKey="Mosca, M" sort="Mosca, M" uniqKey="Mosca M" first="M" last="Mosca">M. Mosca</name><affiliation><mods:affiliation>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</mods:affiliation></affiliation></author><author><name sortKey="Tani, C" sort="Tani, C" uniqKey="Tani C" first="C" last="Tani">C. Tani</name><affiliation><mods:affiliation>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</mods:affiliation></affiliation></author><author><name sortKey="Aringer, M" sort="Aringer, M" uniqKey="Aringer M" first="M" last="Aringer">M. Aringer</name><affiliation><mods:affiliation>University Clinical Center Carl Gustav Carus at the Technical University of Dresden, Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Bombardieri, S" sort="Bombardieri, S" uniqKey="Bombardieri S" first="S" last="Bombardieri">S. Bombardieri</name><affiliation><mods:affiliation>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</mods:affiliation></affiliation></author><author><name sortKey="Boumpas, D" sort="Boumpas, D" uniqKey="Boumpas D" first="D" last="Boumpas">D. Boumpas</name><affiliation><mods:affiliation>University of Crete Medical School, Heraklion, Crete, Greece</mods:affiliation></affiliation></author><author><name sortKey="Brey, R" sort="Brey, R" uniqKey="Brey R" first="R" last="Brey">R. Brey</name><affiliation><mods:affiliation>Department of Medicine/Neurology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Cervera, R" sort="Cervera, R" uniqKey="Cervera R" first="R" last="Cervera">R. Cervera</name><affiliation><mods:affiliation>Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain</mods:affiliation></affiliation></author><author><name sortKey="Doria, A" sort="Doria, A" uniqKey="Doria A" first="A" last="Doria">A. Doria</name><affiliation><mods:affiliation>Division of Rheumatology, University of Padova, Padova, Italy</mods:affiliation></affiliation></author><author><name sortKey="Jayne, D" sort="Jayne, D" uniqKey="Jayne D" first="D" last="Jayne">D. Jayne</name><affiliation><mods:affiliation>Renal Unit, Addenbrooke's Hospital, Cambridge, UK</mods:affiliation></affiliation></author><author><name sortKey="Khamashta, M A" sort="Khamashta, M A" uniqKey="Khamashta M" first="M A" last="Khamashta">M A Khamashta</name><affiliation><mods:affiliation>Lupus Research Unit, Rayne Institute, St Thomas Hospital, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Kuhn, A" sort="Kuhn, A" uniqKey="Kuhn A" first="A" last="Kuhn">A. Kuhn</name><affiliation><mods:affiliation>Department of Dermatology, University of Muenster, Muenster, Germany</mods:affiliation></affiliation></author><author><name sortKey="Gordon, C" sort="Gordon, C" uniqKey="Gordon C" first="C" last="Gordon">C. Gordon</name><affiliation><mods:affiliation>School of Immunity & Infection, University of Birmingham, Birmingham, UK</mods:affiliation></affiliation></author><author><name sortKey="Petri, M" sort="Petri, M" uniqKey="Petri M" first="M" last="Petri">M. Petri</name><affiliation><mods:affiliation>Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Rekvig, O P" sort="Rekvig, O P" uniqKey="Rekvig O" first="O P" last="Rekvig">O P Rekvig</name><affiliation><mods:affiliation>Department of Biochemistry, Institute of Medical Biology, Medical Faculty, University of Tromsø, Tromsø, Norway</mods:affiliation></affiliation></author><author><name sortKey="Schneider, M" sort="Schneider, M" uniqKey="Schneider M" first="M" last="Schneider">M. Schneider</name><affiliation><mods:affiliation>Rheumatology, Clinic of Endocrinology, Diabetology and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany</mods:affiliation></affiliation></author><author><name sortKey="Sherer, Y" sort="Sherer, Y" uniqKey="Sherer Y" first="Y" last="Sherer">Y. Sherer</name><affiliation><mods:affiliation>Hospital Management, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Shoenfeld, Y" sort="Shoenfeld, Y" uniqKey="Shoenfeld Y" first="Y" last="Shoenfeld">Y. Shoenfeld</name><affiliation><mods:affiliation>Department of Medicine B and Center of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Smolen, J S" sort="Smolen, J S" uniqKey="Smolen J" first="J S" last="Smolen">J S Smolen</name><affiliation><mods:affiliation>Department of Rheumatology, Medical University of Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Talarico, R" sort="Talarico, R" uniqKey="Talarico R" first="R" last="Talarico">R. Talarico</name><affiliation><mods:affiliation>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</mods:affiliation></affiliation></author><author><name sortKey="Tincani, A" sort="Tincani, A" uniqKey="Tincani A" first="A" last="Tincani">A. Tincani</name><affiliation><mods:affiliation>UO Reumatologia e Immunologia Clinica, Spedali Civili e Università, Brescia, Italy</mods:affiliation></affiliation></author><author><name sortKey="Van Vollenhoven, R F" sort="Van Vollenhoven, R F" uniqKey="Van Vollenhoven R" first="R F" last="Van Vollenhoven">R F Van Vollenhoven</name><affiliation><mods:affiliation>The Karolinska Institute, Stockholm, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Ward, M M" sort="Ward, M M" uniqKey="Ward M" first="M M" last="Ward">M M Ward</name><affiliation><mods:affiliation>Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, US Department of Health and Human Services, Bethesda, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Werth, V P" sort="Werth, V P" uniqKey="Werth V" first="V P" last="Werth">V P Werth</name><affiliation><mods:affiliation>University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Carmona, L" sort="Carmona, L" uniqKey="Carmona L" first="L" last="Carmona">L. Carmona</name><affiliation><mods:affiliation>Research Unit, Sociedad Española de Reumatología, Madrid, Spain</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2543BEBD79DA58FAB1F39011EBF93221EDEADD0F</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1136/ard.2009.117200</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-7WSDNB4K-T/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000716</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000716</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies</title><author><name sortKey="Mosca, M" sort="Mosca, M" uniqKey="Mosca M" first="M" last="Mosca">M. Mosca</name><affiliation><mods:affiliation>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</mods:affiliation></affiliation></author><author><name sortKey="Tani, C" sort="Tani, C" uniqKey="Tani C" first="C" last="Tani">C. Tani</name><affiliation><mods:affiliation>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</mods:affiliation></affiliation></author><author><name sortKey="Aringer, M" sort="Aringer, M" uniqKey="Aringer M" first="M" last="Aringer">M. Aringer</name><affiliation><mods:affiliation>University Clinical Center Carl Gustav Carus at the Technical University of Dresden, Dresden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Bombardieri, S" sort="Bombardieri, S" uniqKey="Bombardieri S" first="S" last="Bombardieri">S. Bombardieri</name><affiliation><mods:affiliation>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</mods:affiliation></affiliation></author><author><name sortKey="Boumpas, D" sort="Boumpas, D" uniqKey="Boumpas D" first="D" last="Boumpas">D. Boumpas</name><affiliation><mods:affiliation>University of Crete Medical School, Heraklion, Crete, Greece</mods:affiliation></affiliation></author><author><name sortKey="Brey, R" sort="Brey, R" uniqKey="Brey R" first="R" last="Brey">R. Brey</name><affiliation><mods:affiliation>Department of Medicine/Neurology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Cervera, R" sort="Cervera, R" uniqKey="Cervera R" first="R" last="Cervera">R. Cervera</name><affiliation><mods:affiliation>Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain</mods:affiliation></affiliation></author><author><name sortKey="Doria, A" sort="Doria, A" uniqKey="Doria A" first="A" last="Doria">A. Doria</name><affiliation><mods:affiliation>Division of Rheumatology, University of Padova, Padova, Italy</mods:affiliation></affiliation></author><author><name sortKey="Jayne, D" sort="Jayne, D" uniqKey="Jayne D" first="D" last="Jayne">D. Jayne</name><affiliation><mods:affiliation>Renal Unit, Addenbrooke's Hospital, Cambridge, UK</mods:affiliation></affiliation></author><author><name sortKey="Khamashta, M A" sort="Khamashta, M A" uniqKey="Khamashta M" first="M A" last="Khamashta">M A Khamashta</name><affiliation><mods:affiliation>Lupus Research Unit, Rayne Institute, St Thomas Hospital, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Kuhn, A" sort="Kuhn, A" uniqKey="Kuhn A" first="A" last="Kuhn">A. Kuhn</name><affiliation><mods:affiliation>Department of Dermatology, University of Muenster, Muenster, Germany</mods:affiliation></affiliation></author><author><name sortKey="Gordon, C" sort="Gordon, C" uniqKey="Gordon C" first="C" last="Gordon">C. Gordon</name><affiliation><mods:affiliation>School of Immunity & Infection, University of Birmingham, Birmingham, UK</mods:affiliation></affiliation></author><author><name sortKey="Petri, M" sort="Petri, M" uniqKey="Petri M" first="M" last="Petri">M. Petri</name><affiliation><mods:affiliation>Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Rekvig, O P" sort="Rekvig, O P" uniqKey="Rekvig O" first="O P" last="Rekvig">O P Rekvig</name><affiliation><mods:affiliation>Department of Biochemistry, Institute of Medical Biology, Medical Faculty, University of Tromsø, Tromsø, Norway</mods:affiliation></affiliation></author><author><name sortKey="Schneider, M" sort="Schneider, M" uniqKey="Schneider M" first="M" last="Schneider">M. Schneider</name><affiliation><mods:affiliation>Rheumatology, Clinic of Endocrinology, Diabetology and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany</mods:affiliation></affiliation></author><author><name sortKey="Sherer, Y" sort="Sherer, Y" uniqKey="Sherer Y" first="Y" last="Sherer">Y. Sherer</name><affiliation><mods:affiliation>Hospital Management, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Shoenfeld, Y" sort="Shoenfeld, Y" uniqKey="Shoenfeld Y" first="Y" last="Shoenfeld">Y. Shoenfeld</name><affiliation><mods:affiliation>Department of Medicine B and Center of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Smolen, J S" sort="Smolen, J S" uniqKey="Smolen J" first="J S" last="Smolen">J S Smolen</name><affiliation><mods:affiliation>Department of Rheumatology, Medical University of Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Talarico, R" sort="Talarico, R" uniqKey="Talarico R" first="R" last="Talarico">R. Talarico</name><affiliation><mods:affiliation>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</mods:affiliation></affiliation></author><author><name sortKey="Tincani, A" sort="Tincani, A" uniqKey="Tincani A" first="A" last="Tincani">A. Tincani</name><affiliation><mods:affiliation>UO Reumatologia e Immunologia Clinica, Spedali Civili e Università, Brescia, Italy</mods:affiliation></affiliation></author><author><name sortKey="Van Vollenhoven, R F" sort="Van Vollenhoven, R F" uniqKey="Van Vollenhoven R" first="R F" last="Van Vollenhoven">R F Van Vollenhoven</name><affiliation><mods:affiliation>The Karolinska Institute, Stockholm, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Ward, M M" sort="Ward, M M" uniqKey="Ward M" first="M M" last="Ward">M M Ward</name><affiliation><mods:affiliation>Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, US Department of Health and Human Services, Bethesda, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Werth, V P" sort="Werth, V P" uniqKey="Werth V" first="V P" last="Werth">V P Werth</name><affiliation><mods:affiliation>University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Carmona, L" sort="Carmona, L" uniqKey="Carmona L" first="L" last="Carmona">L. Carmona</name><affiliation><mods:affiliation>Research Unit, Sociedad Española de Reumatología, Madrid, Spain</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2010-07">2010-07</date><biblScope unit="volume">69</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1269">1269</biblScope></imprint><idno type="ISSN">0003-4967</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Active disease</term><term>American academy</term><term>Antimalarial drugs</term><term>Antiphospholipid antibodies</term><term>Ares</term><term>Arthritis</term><term>Arthritis rheum</term><term>Autoimmune diseases</term><term>Blood pressure</term><term>Bone mineral density</term><term>Cancer screening</term><term>Cardiovascular</term><term>Cardiovascular disease</term><term>Cardiovascular risk factors</term><term>Clinical practice</term><term>Cognitive impairment</term><term>Cutaneous</term><term>Cutaneous lupus disease area</term><term>Damage development</term><term>Delphi surveys</term><term>Diffuse proliferative lupus glomerulonephritis</term><term>Disease activity</term><term>Disease control</term><term>Disease progression</term><term>Erythematosus</term><term>Eular</term><term>European league</term><term>Further testing</term><term>General population</term><term>Glucocorticoid</term><term>Guideline</term><term>High dose glucocorticoids</term><term>High risk</term><term>Immunosuppressive drugs</term><term>Immunosuppressive therapy</term><term>Inactive disease</term><term>Kidney biopsy</term><term>Laboratory assessment</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lupus nephritis</term><term>Lupus patients</term><term>Monitoring patients</term><term>Observational studies</term><term>Organ damage</term><term>Organ involvement</term><term>Oxford centre</term><term>Patient assessment</term><term>Predictive value</term><term>Premature atherosclerosis</term><term>Preventive measures</term><term>Protective antibodies</term><term>Recommendations table</term><term>Renal</term><term>Renal disease</term><term>Rheum</term><term>Rheumatic diseases</term><term>Rheumatol</term><term>Rheumatology</term><term>Risk factors</term><term>Serum creatinine</term><term>Severity index</term><term>Small group discussion</term><term>Standardised core</term><term>Supplementary material</term><term>Systematic literature review</term><term>Systemic</term><term>Systemic lupus erythematosus</term><term>Task force</term><term>Urine microscopy</term><term>Urine ratio</term><term>Vaccination</term><term>Visual analogue scale</term><term>Worse prognosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Objectives To develop recommendations for monitoring patients with systemic lupus erythematosus (SLE) in clinical practice and observational studies and to develop a standardised core set of variables to monitor SLE. Methods We followed the European League Against Rheumatism (EULAR) standardised procedures for guideline development. The following techniques were applied: nominal groups, Delphi surveys for prioritisation, small group discussion, systematic literature review and two Delphi rounds to obtain agreement. The panel included rheumatologists, internists, dermatologists, a nephrologist and an expert related to national research agencies. The level of evidence and grading of recommendations were determined according to the Levels of Evidence and Grades of Recommendations of the Oxford Centre for Evidence-Based Medicine. Results A total of 10 recommendations have been developed, covering the following aspects: patient assessment, cardiovascular risk factors, other risk factors (osteoporosis, cancer), infection risk (screening, vaccination, monitoring), frequency of assessments, laboratory tests, mucocutaneous involvement, kidney monitoring, neuropsychological manifestations and ophthalmology assessment. A ‘core set’ of minimal variables for the assessment and monitoring of patients with SLE in clinical practice was developed that included some of the recommendations. In addition to the recommendations, indications for specific organ assessments that were viewed as part of good clinical practice were discussed and included in the flow chart. Conclusions A set of recommendations for monitoring patients with SLE in routine clinical practice has been developed. The use of a standardised core set to monitor patients with SLE should facilitate clinical practice, as well as the quality control of care for patients with SLE, and the collection and comparison of data in observational studies.</div></front></TEI><istex><corpusName>bmj</corpusName><keywords><teeft><json:string>lupus</json:string><json:string>erythematosus</json:string><json:string>systemic lupus erythematosus</json:string><json:string>arthritis rheum</json:string><json:string>guideline</json:string><json:string>rheum</json:string><json:string>glucocorticoid</json:string><json:string>clinical practice</json:string><json:string>risk factors</json:string><json:string>rheumatology</json:string><json:string>eular</json:string><json:string>rheumatol</json:string><json:string>cutaneous</json:string><json:string>renal</json:string><json:string>systemic</json:string><json:string>cancer screening</json:string><json:string>monitoring patients</json:string><json:string>observational studies</json:string><json:string>supplementary material</json:string><json:string>blood pressure</json:string><json:string>high risk</json:string><json:string>disease activity</json:string><json:string>cognitive impairment</json:string><json:string>standardised core</json:string><json:string>arthritis</json:string><json:string>ares</json:string><json:string>cardiovascular</json:string><json:string>active disease</json:string><json:string>severity index</json:string><json:string>general population</json:string><json:string>autoimmune diseases</json:string><json:string>cardiovascular disease</json:string><json:string>renal disease</json:string><json:string>rheumatic diseases</json:string><json:string>urine ratio</json:string><json:string>recommendations table</json:string><json:string>patient assessment</json:string><json:string>lupus nephritis</json:string><json:string>lupus erythematosus</json:string><json:string>serum creatinine</json:string><json:string>urine microscopy</json:string><json:string>organ damage</json:string><json:string>european league</json:string><json:string>antimalarial drugs</json:string><json:string>further testing</json:string><json:string>bone mineral density</json:string><json:string>cardiovascular risk factors</json:string><json:string>cutaneous lupus disease area</json:string><json:string>diffuse proliferative lupus glomerulonephritis</json:string><json:string>delphi surveys</json:string><json:string>visual analogue scale</json:string><json:string>premature atherosclerosis</json:string><json:string>immunosuppressive therapy</json:string><json:string>immunosuppressive drugs</json:string><json:string>organ involvement</json:string><json:string>small group discussion</json:string><json:string>protective antibodies</json:string><json:string>high dose glucocorticoids</json:string><json:string>damage development</json:string><json:string>predictive value</json:string><json:string>disease progression</json:string><json:string>worse prognosis</json:string><json:string>kidney biopsy</json:string><json:string>systematic literature review</json:string><json:string>disease control</json:string><json:string>preventive measures</json:string><json:string>laboratory assessment</json:string><json:string>oxford centre</json:string><json:string>lupus patients</json:string><json:string>task force</json:string><json:string>antiphospholipid antibodies</json:string><json:string>american academy</json:string><json:string>inactive disease</json:string><json:string>vaccination</json:string></teeft></keywords><author><json:item><name>M Mosca</name><affiliations><json:string>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</json:string></affiliations></json:item><json:item><name>C Tani</name><affiliations><json:string>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</json:string></affiliations></json:item><json:item><name>M Aringer</name><affiliations><json:string>University Clinical Center Carl Gustav Carus at the Technical University of Dresden, Dresden, Germany</json:string></affiliations></json:item><json:item><name>S Bombardieri</name><affiliations><json:string>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</json:string></affiliations></json:item><json:item><name>D Boumpas</name><affiliations><json:string>University of Crete Medical School, Heraklion, Crete, Greece</json:string></affiliations></json:item><json:item><name>R Brey</name><affiliations><json:string>Department of Medicine/Neurology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</json:string></affiliations></json:item><json:item><name>R Cervera</name><affiliations><json:string>Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain</json:string></affiliations></json:item><json:item><name>A Doria</name><affiliations><json:string>Division of Rheumatology, University of Padova, Padova, Italy</json:string></affiliations></json:item><json:item><name>D Jayne</name><affiliations><json:string>Renal Unit, Addenbrooke's Hospital, Cambridge, UK</json:string></affiliations></json:item><json:item><name>M A Khamashta</name><affiliations><json:string>Lupus Research Unit, Rayne Institute, St Thomas Hospital, London, UK</json:string></affiliations></json:item><json:item><name>A Kuhn</name><affiliations><json:string>Department of Dermatology, University of Muenster, Muenster, Germany</json:string></affiliations></json:item><json:item><name>C Gordon</name><affiliations><json:string>School of Immunity & Infection, University of Birmingham, Birmingham, UK</json:string></affiliations></json:item><json:item><name>M Petri</name><affiliations><json:string>Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</json:string></affiliations></json:item><json:item><name>O P Rekvig</name><affiliations><json:string>Department of Biochemistry, Institute of Medical Biology, Medical Faculty, University of Tromsø, Tromsø, Norway</json:string></affiliations></json:item><json:item><name>M Schneider</name><affiliations><json:string>Rheumatology, Clinic of Endocrinology, Diabetology and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany</json:string></affiliations></json:item><json:item><name>Y Sherer</name><affiliations><json:string>Hospital Management, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel</json:string></affiliations></json:item><json:item><name>Y Shoenfeld</name><affiliations><json:string>Department of Medicine B and Center of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel</json:string></affiliations></json:item><json:item><name>J S Smolen</name><affiliations><json:string>Department of Rheumatology, Medical University of Vienna, Austria</json:string></affiliations></json:item><json:item><name>R Talarico</name><affiliations><json:string>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</json:string></affiliations></json:item><json:item><name>A Tincani</name><affiliations><json:string>UO Reumatologia e Immunologia Clinica, Spedali Civili e Università, Brescia, Italy</json:string></affiliations></json:item><json:item><name>R F van Vollenhoven</name><affiliations><json:string>The Karolinska Institute, Stockholm, Sweden</json:string></affiliations></json:item><json:item><name>M M Ward</name><affiliations><json:string>Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, US Department of Health and Human Services, Bethesda, Maryland, USA</json:string></affiliations></json:item><json:item><name>V P Werth</name><affiliations><json:string>University of Pennsylvania, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item><json:item><name>L Carmona</name><affiliations><json:string>Research Unit, Sociedad Española de Reumatología, Madrid, Spain</json:string></affiliations></json:item></author><articleId><json:string>annrheumdis117200</json:string></articleId><arkIstex>ark:/67375/NVC-7WSDNB4K-T</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>review-article</json:string></originalGenre><abstract>Objectives To develop recommendations for monitoring patients with systemic lupus erythematosus (SLE) in clinical practice and observational studies and to develop a standardised core set of variables to monitor SLE. Methods We followed the European League Against Rheumatism (EULAR) standardised procedures for guideline development. The following techniques were applied: nominal groups, Delphi surveys for prioritisation, small group discussion, systematic literature review and two Delphi rounds to obtain agreement. The panel included rheumatologists, internists, dermatologists, a nephrologist and an expert related to national research agencies. The level of evidence and grading of recommendations were determined according to the Levels of Evidence and Grades of Recommendations of the Oxford Centre for Evidence-Based Medicine. Results A total of 10 recommendations have been developed, covering the following aspects: patient assessment, cardiovascular risk factors, other risk factors (osteoporosis, cancer), infection risk (screening, vaccination, monitoring), frequency of assessments, laboratory tests, mucocutaneous involvement, kidney monitoring, neuropsychological manifestations and ophthalmology assessment. A ‘core set’ of minimal variables for the assessment and monitoring of patients with SLE in clinical practice was developed that included some of the recommendations. In addition to the recommendations, indications for specific organ assessments that were viewed as part of good clinical practice were discussed and included in the flow chart. Conclusions A set of recommendations for monitoring patients with SLE in routine clinical practice has been developed. The use of a standardised core set to monitor patients with SLE should facilitate clinical practice, as well as the quality control of care for patients with SLE, and the collection and comparison of data in observational studies.</abstract><qualityIndicators><score>9.502</score><pdfWordCount>4502</pdfWordCount><pdfCharCount>31445</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>6</pdfPageCount><pdfPageSize>595.277 x 793.702 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>261</abstractWordCount><abstractCharCount>1921</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies</title><pmid><json:string>19892750</json:string></pmid><genre><json:string>review-article</json:string></genre><host><title>Annals of the Rheumatic Diseases</title><language><json:string>unknown</json:string></language><issn><json:string>0003-4967</json:string></issn><eissn><json:string>1468-2060</json:string></eissn><publisherId><json:string>ard</json:string></publisherId><volume>69</volume><issue>7</issue><pages><first>1269</first></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2009-11-05</json:string></date><geogName></geogName><orgName><json:string>Department of Dermatology, University of Muenster, Muenster, Germany</json:string><json:string>University of Birmingham</json:string><json:string>Addenbrooke’s Hospital, Cambridge, UK</json:string><json:string>Research Unit, Sociedad Española</json:string><json:string>National Kidney Foundation</json:string><json:string>University of Padova</json:string><json:string>Johns Hopkins University</json:string><json:string>Department of Medicine/Neurology, The University of Texas Health Science Center</json:string><json:string>Department of Internal Medicine, University of Pisa, Pisa, Italy</json:string><json:string>Systemic Lupus International Collaborating Clinics</json:string><json:string>Hospital Management, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel</json:string><json:string>US Centers for Disease Control and Prevention</json:string><json:string>LUMINA Study Group</json:string><json:string>Intramural Research Program, National Institute of Arthritis</json:string><json:string>Division of Rheumatology</json:string><json:string>US Department of Health and Human Services</json:string><json:string>Department of Medicine B and Center</json:string><json:string>Department of Biochemistry, Institute of Medical Biology, Medical Faculty, University of Tromsø, Tromsø, Norway</json:string><json:string>Tel Aviv University</json:string><json:string>Karolinska Institute, Stockholm, Sweden</json:string><json:string>Technical University</json:string><json:string>Sheba Medical Center</json:string><json:string>Department of Rheumatology, Medical University of Vienna, Austria</json:string><json:string>Lupus Research Unit, Rayne Institute, St Thomas Hospital, London, UK</json:string><json:string>Università</json:string><json:string>Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain</json:string><json:string>University of Pennsylvania</json:string><json:string>EULAR</json:string><json:string>Centre for Evidence-Based Medicine</json:string><json:string>University of Crete Medical School</json:string><json:string>CDC</json:string><json:string>American Academy of Ophthalmology</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Anja Schönbächler</json:string><json:string>Ann Rheum</json:string><json:string>S. Chiara</json:string><json:string>Gustav Carus</json:string><json:string>Authors</json:string><json:string>Juan Antonio</json:string></persName><placeName><json:string>Delphi</json:string><json:string>Tel Aviv</json:string><json:string>Birmingham</json:string><json:string>Germany</json:string><json:string>Greece</json:string><json:string>San Antonio</json:string><json:string>Dresden</json:string><json:string>Brescia</json:string><json:string>UK</json:string><json:string>Heraklion</json:string><json:string>Madrid</json:string><json:string>Baltimore</json:string><json:string>Israel</json:string><json:string>Italy</json:string><json:string>Spain</json:string><json:string>Duesseldorf</json:string></placeName><ref_url><json:string>http://www.kidney.org</json:string><json:string>http://ard.bmj.com</json:string></ref_url><ref_bibl><json:string>Bernatsky et al</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/NVC-7WSDNB4K-T</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - rheumatology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - arthritis & rheumatology</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - General Biochemistry, Genetics and Molecular Biology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Immunology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Rheumatology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1136/ard.2009.117200</json:string></doi><id>2543BEBD79DA58FAB1F39011EBF93221EDEADD0F</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-7WSDNB4K-T/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-7WSDNB4K-T/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/NVC-7WSDNB4K-T/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://publisher-list.data.istex.fr">BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><availability><licence><p>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</p></availability><date>2009-11-05</date></publicationStmt><notesStmt><note type="review-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies</title><author xml:id="author-0000"><persName><forename type="first">M</forename><surname>Mosca</surname></persName><affiliation>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</affiliation></author><author xml:id="author-0001"><persName><forename type="first">C</forename><surname>Tani</surname></persName><affiliation>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</affiliation></author><author xml:id="author-0002"><persName><forename type="first">M</forename><surname>Aringer</surname></persName><affiliation>University Clinical Center Carl Gustav Carus at the Technical University of Dresden, Dresden, Germany</affiliation></author><author xml:id="author-0003"><persName><forename type="first">S</forename><surname>Bombardieri</surname></persName><affiliation>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</affiliation></author><author xml:id="author-0004"><persName><forename type="first">D</forename><surname>Boumpas</surname></persName><affiliation>University of Crete Medical School, Heraklion, Crete, Greece</affiliation></author><author xml:id="author-0005"><persName><forename type="first">R</forename><surname>Brey</surname></persName><affiliation>Department of Medicine/Neurology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</affiliation></author><author xml:id="author-0006"><persName><forename type="first">R</forename><surname>Cervera</surname></persName><affiliation>Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain</affiliation></author><author xml:id="author-0007"><persName><forename type="first">A</forename><surname>Doria</surname></persName><affiliation>Division of Rheumatology, University of Padova, Padova, Italy</affiliation></author><author xml:id="author-0008"><persName><forename type="first">D</forename><surname>Jayne</surname></persName><affiliation>Renal Unit, Addenbrooke's Hospital, Cambridge, UK</affiliation></author><author xml:id="author-0009"><persName><forename type="first">M A</forename><surname>Khamashta</surname></persName><affiliation>Lupus Research Unit, Rayne Institute, St Thomas Hospital, London, UK</affiliation></author><author xml:id="author-0010"><persName><forename type="first">A</forename><surname>Kuhn</surname></persName><affiliation>Department of Dermatology, University of Muenster, Muenster, Germany</affiliation></author><author xml:id="author-0011"><persName><forename type="first">C</forename><surname>Gordon</surname></persName><affiliation>School of Immunity & Infection, University of Birmingham, Birmingham, UK</affiliation></author><author xml:id="author-0012"><persName><forename type="first">M</forename><surname>Petri</surname></persName><affiliation>Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</affiliation></author><author xml:id="author-0013"><persName><forename type="first">O P</forename><surname>Rekvig</surname></persName><affiliation>Department of Biochemistry, Institute of Medical Biology, Medical Faculty, University of Tromsø, Tromsø, Norway</affiliation></author><author xml:id="author-0014"><persName><forename type="first">M</forename><surname>Schneider</surname></persName><affiliation>Rheumatology, Clinic of Endocrinology, Diabetology and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany</affiliation></author><author xml:id="author-0015"><persName><forename type="first">Y</forename><surname>Sherer</surname></persName><affiliation>Hospital Management, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel</affiliation></author><author xml:id="author-0016"><persName><forename type="first">Y</forename><surname>Shoenfeld</surname></persName><affiliation>Department of Medicine B and Center of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel</affiliation></author><author xml:id="author-0017"><persName><forename type="first">J S</forename><surname>Smolen</surname></persName><affiliation>Department of Rheumatology, Medical University of Vienna, Austria</affiliation></author><author xml:id="author-0018"><persName><forename type="first">R</forename><surname>Talarico</surname></persName><affiliation>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</affiliation></author><author xml:id="author-0019"><persName><forename type="first">A</forename><surname>Tincani</surname></persName><affiliation>UO Reumatologia e Immunologia Clinica, Spedali Civili e Università, Brescia, Italy</affiliation></author><author xml:id="author-0020"><persName><forename type="first">R F</forename><surname>van Vollenhoven</surname></persName><affiliation>The Karolinska Institute, Stockholm, Sweden</affiliation></author><author xml:id="author-0021"><persName><forename type="first">M M</forename><surname>Ward</surname></persName><affiliation>Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, US Department of Health and Human Services, Bethesda, Maryland, USA</affiliation></author><author xml:id="author-0022"><persName><forename type="first">V P</forename><surname>Werth</surname></persName><affiliation>University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation></author><author xml:id="author-0023"><persName><forename type="first">L</forename><surname>Carmona</surname></persName><affiliation>Research Unit, Sociedad Española de Reumatología, Madrid, Spain</affiliation></author><idno type="istex">2543BEBD79DA58FAB1F39011EBF93221EDEADD0F</idno><idno type="ark">ark:/67375/NVC-7WSDNB4K-T</idno><idno type="DOI">10.1136/ard.2009.117200</idno><idno type="href">annrheumdis-69-1269.pdf</idno><idno type="article-id">annrheumdis117200</idno><idno type="PMID">19892750</idno><idno type="local">annrheumdis;69/7/1269</idno></analytic><monogr><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="pISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><idno type="publisher-id">ard</idno><idno type="PublisherID-hwp">annrheumdis</idno><idno type="PublisherID-nlm-ta">Ann Rheum Dis</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2010-07"></date><biblScope unit="volume">69</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1269">1269</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009-11-05</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Objectives To develop recommendations for monitoring patients with systemic lupus erythematosus (SLE) in clinical practice and observational studies and to develop a standardised core set of variables to monitor SLE. Methods We followed the European League Against Rheumatism (EULAR) standardised procedures for guideline development. The following techniques were applied: nominal groups, Delphi surveys for prioritisation, small group discussion, systematic literature review and two Delphi rounds to obtain agreement. The panel included rheumatologists, internists, dermatologists, a nephrologist and an expert related to national research agencies. The level of evidence and grading of recommendations were determined according to the Levels of Evidence and Grades of Recommendations of the Oxford Centre for Evidence-Based Medicine. Results A total of 10 recommendations have been developed, covering the following aspects: patient assessment, cardiovascular risk factors, other risk factors (osteoporosis, cancer), infection risk (screening, vaccination, monitoring), frequency of assessments, laboratory tests, mucocutaneous involvement, kidney monitoring, neuropsychological manifestations and ophthalmology assessment. A ‘core set’ of minimal variables for the assessment and monitoring of patients with SLE in clinical practice was developed that included some of the recommendations. In addition to the recommendations, indications for specific organ assessments that were viewed as part of good clinical practice were discussed and included in the flow chart. Conclusions A set of recommendations for monitoring patients with SLE in routine clinical practice has been developed. The use of a standardised core set to monitor patients with SLE should facilitate clinical practice, as well as the quality control of care for patients with SLE, and the collection and comparison of data in observational studies.</p></abstract></profileDesc><revisionDesc><change when="2009-11-05">Created</change><change when="2010-07">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-7WSDNB4K-T/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="review-article"><front><journal-meta><journal-id journal-id-type="hwp">annrheumdis</journal-id><journal-id journal-id-type="nlm-ta">Ann Rheum Dis</journal-id><journal-id journal-id-type="publisher-id">ard</journal-id><journal-title>Annals of the Rheumatic Diseases</journal-title><abbrev-journal-title abbrev-type="publisher">Ann Rheum Dis</abbrev-journal-title><abbrev-journal-title>Ann Rheum Dis</abbrev-journal-title><issn pub-type="ppub">0003-4967</issn><issn pub-type="epub">1468-2060</issn><publisher><publisher-name>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">annrheumdis117200</article-id><article-id pub-id-type="doi">10.1136/ard.2009.117200</article-id><article-id pub-id-type="other">annrheumdis;69/7/1269</article-id><article-id pub-id-type="other">annrheumdis;ard.2009.117200</article-id><article-id pub-id-type="pmid">19892750</article-id><article-id pub-id-type="other">1269</article-id><article-id pub-id-type="other">ard.2009.117200</article-id><article-categories><subj-group subj-group-type="heading"><subject>Recommendations</subject></subj-group></article-categories><title-group><article-title>European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mosca</surname><given-names>M</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tani</surname><given-names>C</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Aringer</surname><given-names>M</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bombardieri</surname><given-names>S</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Boumpas</surname><given-names>D</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Brey</surname><given-names>R</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Cervera</surname><given-names>R</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Doria</surname><given-names>A</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Jayne</surname><given-names>D</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Khamashta</surname><given-names>M A</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Kuhn</surname><given-names>A</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Gordon</surname><given-names>C</given-names></name><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Petri</surname><given-names>M</given-names></name><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Rekvig</surname><given-names>O P</given-names></name><xref ref-type="aff" rid="A12">12</xref></contrib><contrib contrib-type="author"><name><surname>Schneider</surname><given-names>M</given-names></name><xref ref-type="aff" rid="A13">13</xref></contrib><contrib contrib-type="author"><name><surname>Sherer</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="A14">14</xref></contrib><contrib contrib-type="author"><name><surname>Shoenfeld</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="A15">15</xref></contrib><contrib contrib-type="author"><name><surname>Smolen</surname><given-names>J S</given-names></name><xref ref-type="aff" rid="A16">16</xref></contrib><contrib contrib-type="author"><name><surname>Talarico</surname><given-names>R</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tincani</surname><given-names>A</given-names></name><xref ref-type="aff" rid="A17">17</xref></contrib><contrib contrib-type="author"><name><surname>van Vollenhoven</surname><given-names>R F</given-names></name><xref ref-type="aff" rid="A18">18</xref></contrib><contrib contrib-type="author"><name><surname>Ward</surname><given-names>M M</given-names></name><xref ref-type="aff" rid="A19">19</xref></contrib><contrib contrib-type="author"><name><surname>Werth</surname><given-names>V P</given-names></name><xref ref-type="aff" rid="A20">20</xref></contrib><contrib contrib-type="author"><name><surname>Carmona</surname><given-names>L</given-names></name><xref ref-type="aff" rid="A21">21</xref></contrib></contrib-group><aff id="A1"><label>1</label>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</aff><aff id="A2"><label>2</label>University Clinical Center Carl Gustav Carus at the Technical University of Dresden, Dresden, Germany</aff><aff id="A3"><label>3</label>University of Crete Medical School, Heraklion, Crete, Greece</aff><aff id="A4"><label>4</label>Department of Medicine/Neurology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</aff><aff id="A5"><label>5</label>Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain</aff><aff id="A6"><label>6</label>Division of Rheumatology, University of Padova, Padova, Italy</aff><aff id="A7"><label>7</label>Renal Unit, Addenbrooke's Hospital, Cambridge, UK</aff><aff id="A8"><label>8</label>Lupus Research Unit, Rayne Institute, St Thomas Hospital, London, UK</aff><aff id="A9"><label>9</label>Department of Dermatology, University of Muenster, Muenster, Germany</aff><aff id="A10"><label>10</label>School of Immunity & Infection, University of Birmingham, Birmingham, UK</aff><aff id="A11"><label>11</label>Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</aff><aff id="A12"><label>12</label>Department of Biochemistry, Institute of Medical Biology, Medical Faculty, University of Tromsø, Tromsø, Norway</aff><aff id="A13"><label>13</label>Rheumatology, Clinic of Endocrinology, Diabetology and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany</aff><aff id="A14"><label>14</label>Hospital Management, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel</aff><aff id="A15"><label>15</label>Department of Medicine B and Center of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel</aff><aff id="A16"><label>16</label>Department of Rheumatology, Medical University of Vienna, Austria</aff><aff id="A17"><label>17</label>UO Reumatologia e Immunologia Clinica, Spedali Civili e Università, Brescia, Italy</aff><aff id="A18"><label>18</label>The Karolinska Institute, Stockholm, Sweden</aff><aff id="A19"><label>19</label>Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, US Department of Health and Human Services, Bethesda, Maryland, USA</aff><aff id="A20"><label>20</label>University of Pennsylvania, Philadelphia, Pennsylvania, USA</aff><aff id="A21"><label>21</label>Research Unit, Sociedad Española de Reumatología, Madrid, Spain</aff><author-notes><corresp><label>Correspondence to</label> Dr Marta Mosca, University of Pisa, via Roma 67, Ospedale S. Chiara, Pisa, 56126, Italy; <email xlink:type="simple">marta.mosca@int.med.unipi.it</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2010</year></pub-date><pub-date pub-type="epub-original"><month>7</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>5</day><month>11</month><year>2009</year></pub-date><volume>69</volume><volume-id pub-id-type="other">69</volume-id><volume-id pub-id-type="other">69</volume-id><issue>7</issue><issue-id pub-id-type="other">annrheumdis;69/7</issue-id><issue-id pub-id-type="other">7</issue-id><issue-id pub-id-type="other">69/7</issue-id><fpage>1269</fpage><history><date date-type="accepted"><day>19</day><month>10</month><year>2009</year></date></history><permissions><copyright-statement>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</copyright-statement><copyright-year>2010</copyright-year></permissions><self-uri content-type="pdf" xlink:role="full-text" xlink:href="annrheumdis-69-1269.pdf"></self-uri><abstract><sec><title>Objectives</title><p>To develop recommendations for monitoring patients with systemic lupus erythematosus (SLE) in clinical practice and observational studies and to develop a standardised core set of variables to monitor SLE.</p></sec><sec><title>Methods</title><p>We followed the European League Against Rheumatism (EULAR) standardised procedures for guideline development. The following techniques were applied: nominal groups, Delphi surveys for prioritisation, small group discussion, systematic literature review and two Delphi rounds to obtain agreement. The panel included rheumatologists, internists, dermatologists, a nephrologist and an expert related to national research agencies. The level of evidence and grading of recommendations were determined according to the Levels of Evidence and Grades of Recommendations of the Oxford Centre for Evidence-Based Medicine.</p></sec><sec><title>Results</title><p>A total of 10 recommendations have been developed, covering the following aspects: patient assessment, cardiovascular risk factors, other risk factors (osteoporosis, cancer), infection risk (screening, vaccination, monitoring), frequency of assessments, laboratory tests, mucocutaneous involvement, kidney monitoring, neuropsychological manifestations and ophthalmology assessment. A ‘core set’ of minimal variables for the assessment and monitoring of patients with SLE in clinical practice was developed that included some of the recommendations. In addition to the recommendations, indications for specific organ assessments that were viewed as part of good clinical practice were discussed and included in the flow chart.</p></sec><sec><title>Conclusions</title><p>A set of recommendations for monitoring patients with SLE in routine clinical practice has been developed. The use of a standardised core set to monitor patients with SLE should facilitate clinical practice, as well as the quality control of care for patients with SLE, and the collection and comparison of data in observational studies.</p></sec></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Mosca</namePart><affiliation>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Tani</namePart><affiliation>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Aringer</namePart><affiliation>University Clinical Center Carl Gustav Carus at the Technical University of Dresden, Dresden, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Bombardieri</namePart><affiliation>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Boumpas</namePart><affiliation>University of Crete Medical School, Heraklion, Crete, Greece</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Brey</namePart><affiliation>Department of Medicine/Neurology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Cervera</namePart><affiliation>Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Doria</namePart><affiliation>Division of Rheumatology, University of Padova, Padova, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Jayne</namePart><affiliation>Renal Unit, Addenbrooke's Hospital, Cambridge, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M A</namePart><namePart type="family">Khamashta</namePart><affiliation>Lupus Research Unit, Rayne Institute, St Thomas Hospital, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kuhn</namePart><affiliation>Department of Dermatology, University of Muenster, Muenster, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Gordon</namePart><affiliation>School of Immunity & Infection, University of Birmingham, Birmingham, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Petri</namePart><affiliation>Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O P</namePart><namePart type="family">Rekvig</namePart><affiliation>Department of Biochemistry, Institute of Medical Biology, Medical Faculty, University of Tromsø, Tromsø, Norway</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Schneider</namePart><affiliation>Rheumatology, Clinic of Endocrinology, Diabetology and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Sherer</namePart><affiliation>Hospital Management, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Shoenfeld</namePart><affiliation>Department of Medicine B and Center of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J S</namePart><namePart type="family">Smolen</namePart><affiliation>Department of Rheumatology, Medical University of Vienna, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Talarico</namePart><affiliation>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Tincani</namePart><affiliation>UO Reumatologia e Immunologia Clinica, Spedali Civili e Università, Brescia, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R F</namePart><namePart type="family">van Vollenhoven</namePart><affiliation>The Karolinska Institute, Stockholm, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M M</namePart><namePart type="family">Ward</namePart><affiliation>Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, US Department of Health and Human Services, Bethesda, Maryland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V P</namePart><namePart type="family">Werth</namePart><affiliation>University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Carmona</namePart><affiliation>Research Unit, Sociedad Española de Reumatología, Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="review-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><dateIssued encoding="w3cdtf">2010-07</dateIssued><dateCreated encoding="w3cdtf">2009-11-05</dateCreated><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract>Objectives To develop recommendations for monitoring patients with systemic lupus erythematosus (SLE) in clinical practice and observational studies and to develop a standardised core set of variables to monitor SLE. Methods We followed the European League Against Rheumatism (EULAR) standardised procedures for guideline development. The following techniques were applied: nominal groups, Delphi surveys for prioritisation, small group discussion, systematic literature review and two Delphi rounds to obtain agreement. The panel included rheumatologists, internists, dermatologists, a nephrologist and an expert related to national research agencies. The level of evidence and grading of recommendations were determined according to the Levels of Evidence and Grades of Recommendations of the Oxford Centre for Evidence-Based Medicine. Results A total of 10 recommendations have been developed, covering the following aspects: patient assessment, cardiovascular risk factors, other risk factors (osteoporosis, cancer), infection risk (screening, vaccination, monitoring), frequency of assessments, laboratory tests, mucocutaneous involvement, kidney monitoring, neuropsychological manifestations and ophthalmology assessment. A ‘core set’ of minimal variables for the assessment and monitoring of patients with SLE in clinical practice was developed that included some of the recommendations. In addition to the recommendations, indications for specific organ assessments that were viewed as part of good clinical practice were discussed and included in the flow chart. Conclusions A set of recommendations for monitoring patients with SLE in routine clinical practice has been developed. The use of a standardised core set to monitor patients with SLE should facilitate clinical practice, as well as the quality control of care for patients with SLE, and the collection and comparison of data in observational studies.</abstract><relatedItem type="host"><titleInfo><title>Annals of the Rheumatic Diseases</title></titleInfo><titleInfo type="abbreviated"><title>Ann Rheum Dis</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0003-4967</identifier><identifier type="eISSN">1468-2060</identifier><identifier type="PublisherID">ard</identifier><identifier type="PublisherID-hwp">annrheumdis</identifier><identifier type="PublisherID-nlm-ta">Ann Rheum Dis</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>1269</start></extent></part></relatedItem><identifier type="istex">2543BEBD79DA58FAB1F39011EBF93221EDEADD0F</identifier><identifier type="ark">ark:/67375/NVC-7WSDNB4K-T</identifier><identifier type="DOI">10.1136/ard.2009.117200</identifier><identifier type="href">annrheumdis-69-1269.pdf</identifier><identifier type="ArticleID">annrheumdis117200</identifier><identifier type="PMID">19892750</identifier><identifier type="local">annrheumdis;69/7/1269</identifier><accessCondition type="use and reproduction" contentType="copyright">Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</recordContentSource><recordOrigin>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-7WSDNB4K-T/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000716 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000716 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:2543BEBD79DA58FAB1F39011EBF93221EDEADD0F
|texte= European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies
}}
| This area was generated with Dilib version V0.6.33. |  |